home / stock / fhtx / fhtx quote
Last: | $5.51 |
---|---|
Change Percent: | -0.86% |
Open: | $5.86 |
Close: | $5.51 |
High: | $6.02 |
Low: | $5.47 |
Volume: | 60,661 |
Last Trade Date Time: | 05/17/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$5.51 | $5.86 | $5.51 | $6.02 | $5.47 | 60,661 | 05-17-2024 |
$5.81 | $5.3942 | $5.81 | $5.88 | $5.3942 | 70,611 | 05-16-2024 |
$5.29 | $5.82 | $5.29 | $5.945 | $5.22 | 79,264 | 05-15-2024 |
$5.67 | $5.82 | $5.67 | $5.915 | $5.33 | 85,904 | 05-14-2024 |
$5.67 | $5.63 | $5.67 | $6.07 | $5.52 | 59,781 | 05-13-2024 |
$5.56 | $5.99 | $5.56 | $6.01 | $5.11 | 146,096 | 05-10-2024 |
$5.94 | $5.93 | $5.94 | $6.5035 | $5.88 | 82,536 | 05-09-2024 |
$5.98 | $5.51 | $5.98 | $5.98 | $5.51 | 55,696 | 05-08-2024 |
$5.63 | $5.83 | $5.63 | $6.0343 | $5.62 | 58,265 | 05-07-2024 |
$5.83 | $6.04 | $5.83 | $6.29 | $5.83 | 30,420 | 05-06-2024 |
$5.99 | $6.35 | $5.99 | $6.5199 | $5.82 | 48,320 | 05-03-2024 |
$6.11 | $6 | $6.11 | $6.35 | $5.85 | 68,642 | 05-02-2024 |
$5.86 | $5.48 | $5.86 | $6.25 | $5.48 | 60,654 | 05-01-2024 |
$5.46 | $5.57 | $5.46 | $5.68 | $5.44 | 28,866 | 04-30-2024 |
$5.73 | $5.62 | $5.73 | $5.9 | $5.61 | 16,463 | 04-29-2024 |
$5.49 | $5.25 | $5.49 | $5.545 | $5.16 | 35,367 | 04-26-2024 |
$5.23 | $5.04 | $5.23 | $5.31 | $4.8 | 48,749 | 04-25-2024 |
$5.21 | $5.21 | $5.21 | $5.62 | $5.15 | 111,112 | 04-24-2024 |
$5.16 | $5.2 | $5.16 | $5.375 | $5.09 | 45,759 | 04-23-2024 |
$5.05 | $5.31 | $5.05 | $5.4 | $4.96 | 77,557 | 04-22-2024 |
News, Short Squeeze, Breakout and More Instantly...
Foghorn Therapeutics Inc. Company Name:
FHTX Stock Symbol:
NASDAQ Market:
2024-05-06 12:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Dose escalation in FHD-286 combination trial in AML continues to progress with clinical data expected in the second half of 2024; potential to be a first-in-class oral broad-based differentiation therapeutic in AML IND filing submitted for FHD-909, a first-in-class oral BRM (SMARCA2) sele...
2024-04-26 18:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...